CVE-2022-45611

CVE-2022-45611 is a critical-severity vulnerability in Fresenius-kabi Pharmahelp Firmware with a CVSS 3.x base score of 9.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-522.

Key facts

Description

An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.

Frequently asked questions

What is CVE-2022-45611?
An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
How severe is CVE-2022-45611?
CVE-2022-45611 has a CVSS 3.x base score of 9.8, rated critical severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2022-45611 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (57th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2022-45611?
CVE-2022-45611 affects Fresenius-kabi Pharmahelp Firmware. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2022-45611?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its critical severity, prioritise patching exposed systems.
When was CVE-2022-45611 published?
CVE-2022-45611 was published on 2023-08-22 and last updated on 2026-06-17.

References

Affected products (1)

Other CWE-522 (Insufficiently Protected Credentials) vulnerabilities

Browse all CWE-522 (Insufficiently Protected Credentials) vulnerabilities →